AbD Serotec entered a supply agreement with Spinreact related to diagnostic development. Initially, Spinreact will incorporate two antibodies in a series of clinical diagnostic kits.
The deal calls for AbD Serotec to continuously supply Spinreact with antibody material. “The fast turn-around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of development and validation, allowing Spinreact to bring new clinical diagnostic reagents for human diseases to the market in the shortest possible timeframe,” says Josep Puig, CEO of Spinreact.
“Today's news represents another example of the higher value-added projects that AbD Serotec is increasingly pursuing in line with our strategy to increase our efforts on the diagnostics side of the business,” notes Dieter Feger, svp and head of AbD Serotec.
The deal with Spinreact is AbD Sertotec’s second in the diagnostic space. In July 2008 Phadia inked an agreement to implement HuCAL-based recombinant antibodies in its marketed autoimmune tests Varelisa™ and EliA™.